Ocrelizumab accepted for EMA review
Ocrelizumab accepted for EMA review
Roche has announced that the European Medicines Agency (EMA) has validated the company’s Marketing Authorisation Application (MAA) of ocrelizumab for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) in the European Union (EU)...Read more - http://www.ms-uk.org/MSnews
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 11482 Views
-
Last post by NHE
-
- 0 Replies
- 1122 Views
-
Last post by NHE
-
- 0 Replies
- 1903 Views
-
Last post by frodo
-
- 0 Replies
- 1234 Views
-
Last post by frodo
-
- 0 Replies
- 2051 Views
-
Last post by NHE
-
- 0 Replies
- 1685 Views
-
Last post by frodo
-
- 0 Replies
- 1259 Views
-
Last post by NHE
-
- 1 Replies
- 1751 Views
-
Last post by frodo
-
- 0 Replies
- 2412 Views
-
Last post by NHE